NCT04251741View on ClinicalTrials.gov

Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions
Rheumatoid Arthritis
Interventions
DIAGNOSTIC_TEST

Adalimumab trough concentration

In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration

OTHER

Usual care

In the usual care group, switch to subsequent biological is based on secondary randomisation

Trial Locations (2)

6574NA

Sint Maartenskliniek, Ubbergen

1056AB

Reade Rheumatology Research Institute, Amsterdam

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Sint Maartenskliniek

OTHER

lead

Reade Rheumatology Research Institute

OTHER